The stock of Akebia Therapeutics Incorporated (NASDAQ:AKBA) registered a decrease of 3.7% in short interest. AKBA’s total short interest was 2.72M shares in April as published by FINRA. Its down 3.7% from 2.82M shares, reported previously. With 446,500 shares average volume, it will take short sellers 6 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Incorporated’s float is 17.69%. The stock decreased 1.24% or $0.12 on April 8, hitting $9.56. Akebia Therapeutics Inc (NASDAQ:AKBA) has risen 26.96% since September 2, 2015 and is uptrending. It has outperformed by 21.89% the S&P500.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $358.24 million. The Firm is focused on the development of therapeutics based on hypoxia inducible factor biology and the commercialization of these products for patients with kidney disease. It currently has negative earnings. The Company’s lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy.
The institutional sentiment decreased to 1.89 in 2015 Q3. Its down 2.94, from 4.83 in 2015Q2. The ratio turned negative, as 12 funds sold all Akebia Therapeutics Inc shares owned while 15 reduced positions. 19 funds bought stakes while 32 increased positions. They now own 19.74 million shares or 21.59% less from 25.18 million shares in 2015Q2.
Novo A S holds 1.51% of its portfolio in Akebia Therapeutics Inc for 1.52 million shares. P.A.W. Capital Corp owns 130,000 shares or 1.44% of their US portfolio. Moreover, Eam Investors Llc has 0.37% invested in the company for 241,440 shares. The Florida-based Eagle Asset Management Inc has invested 0.22% in the stock. Perceptive Advisors Llc, a New York-based fund reported 260,000 shares.
Out of 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Akebia Therapeutics Inc was the topic in 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on March 15 with “Buy” rating.
Akebia Therapeutics Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.